Homepage Plandai Biotechnology
Seite 2 von 5 Neuester Beitrag: 18.10.21 15:42 | ||||
| Eröffnet am: | 03.02.14 12:41 | von: Andrew6466 | Anzahl Beiträge: | 106 |
| Neuester Beitrag: | 18.10.21 15:42 | von: pennystockfi. | Leser gesamt: | 21.996 |
| Forum: | Hot-Stocks | Leser heute: | 9 | |
| Bewertet mit: |  | |||
| Seite: < 1 | | 3 | 4 | 5 > | ||||
PS: Order in USA ist drin - mal sehen wie ich die Stücke bekomme.......
Sind nur knapp 200 Mio draußen - keine Mrd-Stücke - gut so !!!
Float ??? Frei Handelbare Stücke - hat jemand eine Ahnung ????????
Jetzt können die 2 Dollar je Aktie wieder kommen - bis Januar 2017 !! *g*
Damals war PLPL mal kurz bei 2 Dollar/ je Aktie !!
SOURCE: Plandai Biotechnology, Inc.
Plandai Biotechnology, Inc.
October 30, 2013 09:00 ET
Plandai Biotechnology, Inc. to Enter Medical Marijuana Field With Phyto Cannabinoid Extract
Announces Formation of Cannabis Biosciences, Inc. to Develop Pharmaceutical Applications
SEATTLE, WA--(Marketwired - Oct 30, 2013) - Plandaí Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutriceutical, and pharmaceutical, today announced that it has formed a new wholly-owned subsidiary, Cannabis Biosciences, Inc., in Delaware, for the purpose of developing and testing a new Phytofare™ botanical extract derived from cannabis.
Preliminarily dubbed Phytofare™ Phyto-cannabinoid Complex, the new extract will share a similar extraction process to the other Phytofare™ products and is expected to demonstrate the same high levels of bioavailability and purity. During the extraction process the company could also remove the psychoactive compound (THC), rendering a botanical drug that offers many of the medicinal benefits of cannabis without the perceived negative side effects and social stigma.
Cannabis has shown strong medicinal potential across multiple fields in numerous independent clinical trials, including controlling symptoms of ALS (Lou Gehrig's Disease), Multiple Sclerosis and Crohn's disease, managing insulin levels in diabetics, and fighting breast cancer. THC has also been shown to help in reducing brain tumors and slowing the advance of Alzheimer's. In fact, the United States Department of Health and Human Services states in a 2001 U.S. Patent Application (Patent Number 6,630,507) that:
"Cannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and HIV dementia. Nonpsychoactive cannabinoids, such as cannabidoil, are particularly advantageous to use because they avoid toxicity that is encountered with psychoactive cannabinoids at high doses useful in the method of the present invention."
Roger Duffield, Chairman and Chief Executive Officer of Plandaí Biotechnology, commented, "For the past twelve months, the Plandaí team has been working with cannabis to first ascertain if our patent-pending process could produce a phyto-cannabinoid extract that exhibits the same high bioavailability of our other Phytofare™ products. Working with cannabis presents unique challenges in that it produces a very sticky oil that must be dealt with -- and that only after navigating the complex legal obstacles. However, the medicinal opportunities associated with phyto-cannabinoids are simply too great to ignore."
Mr. Duffield indicated that, having completed the science, preliminary bioavailability testing should commence in early 2014 with clinical trials commencing later in the year to pursue various pharmaceutical and nutraceutical applications.
About Plandaí Biotechnology, Inc.
Plandaí Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandaí Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its patented Phytofare™ extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.
Safe Harbor Statement
The information provided may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Plandaí's ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Plandaí is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.
Contact Information
Contact:
Andrew Beyer
Phone: 619-202-7456
Email: investor@Plandaíbiotech.com
Der Anfang ist gemacht - heute auch wieder schön im Plus.
Wer ist noch dabei ?
Wo seht ihr das Kursziel die Nächste Zeit ?
m.M. dürften 10 US-Cent demnächst durchaus drin sein - was meint ihr ??
Bin gespannt was bis 22:00 Uhr noch passiert bei PLPL.
Moderation
Zeitpunkt: 20.10.16 17:19
Aktion: Löschung des Beitrages
Kommentar: Urheberrechtsverletzung, vollständige Quellenangabe fehlt
Zeitpunkt: 20.10.16 17:19
Aktion: Löschung des Beitrages
Kommentar: Urheberrechtsverletzung, vollständige Quellenangabe fehlt
Cannabis
Plandaí and Cannabis – What is Our Role?
When Plandaí first announced its intention to produce a Phytofare™ Cannabinoid Extract, we were inundated with phone calls and emails—the majority of which wanted to know when and where they could buy some. Since that time, we’ve read different articles and blog posts speculating that Plandaí is growing marijuana on its South Africa plantation and importing its extract to Washington under the Diego Pellicer brand name.
With all of this misinformation out there, we felt it appropriate to “set the record straight” with respect to Plandaí and its involvement in the marijuana industry.
First, Plandaí is NOT presently producing any type of cannabis extract nor are we farming cannabis in South Africa, Washington or anywhere else. There are many reasons for this, but primarily we recognize that cannabis cultivation and extract production is illegal—everywhere—unless you have special permission from the government. Notwithstanding recent legislation in Washington and Colorado, growing, processing, possessing and selling marijuana in any form is still illegal on the federal level. Plandaí has no intention of crossing this line. Internationally, growing marijuana is illegal, especially in South Africa and other countries where we operate.
Initially, our attorneys believed we could set up a lab and begin testing in Washington. We set this process in motion by designing the equipment and reaching out to local scientists and researchers. We then determined that, if followed through upon, our activities could potentially violate federal laws and we immediately halted any efforts to produce an extract in the US.
With that being said, Plandaí believes that cannabis shows great medical potential. Unfortunately, very little testing has been done in a true, double-blind, controlled human clinical environment. Much of what we know is either anecdotal or backed by small lab-scale studies. We have developed the science that will allow us to produce a highly bioavailable cannabinoid complex. This new product should enable us to deliver a clinical dose of cannabinoids directly to human tissue and, theoretically, even cross the blood-brain barrier, enabling us to treat neuron disorders. Without testing, however, this is all theoretical.
Plandaí is actively working with several government agencies in hopes of being granted permission to commence testing our cannabinoid product. Once this permission is received, it will take us about ninety days to set up an extraction lab and produce the first extract. This extract will then be tested for purity and undergo a full chemical profile. Only then will be begin animal studies to determine what, if any, medicinal benefits are present. Favorable lab studies will eventually lead to human clinical trials but, again, only with proper government sanctioning.
We believe that favorable clinical trials will eventually pave the way for government acceptance. Especially for products like Plandaí’s which will have no psychoactive effects. Once we reach that point, we will have several decisions to make: Do we produce an extract locally? Do we license the technology to a third party? Do we farm our own product or purchase from a local grower? We cannot begin to answer these questions until we first have clinical results and then take account of the legal landscape at such future date.
The takeaway for our investors is that Plandaí remains committed to conducting ongoing research with a variety of different plants including cannabis and that this research will go forward as fast as the legal climate permits. Until such time, we remain committed to obeying the laws—federal, state, and international—while we continue to champion for changes to those laws and establish industry standards. We have a fiduciary responsibility to our shareholders to ensure that our company is built on a solid foundation of science, ethics, frugality, and adherence to the laws of the land.
We will continue to keep our shareholders aware of any changes to legislation and any government-approved dispensations we obtain.
- Plandaí and Cannabis – What is Our Role?
- Cannabis Law
- The Need for Standards in the Cannabis Industry
- Cancer
- Epilepsy
- Multiple Sclerosis
- Parkinson's Disease
- Post Traumatic Stress Disorder
Cannabis Biosciences is the parent company of Plandaí Biotechnology Uruguay, S.A., and holds the license from Plandaí to conduct all product development, clinical trials, sales and marketing for Plandaí’s cannabis-derived bioavailable extract.
http://ih.advfn.com/p.php?pid=nmona&article=72493680
LONDON, UNITED KINGDOM--(Marketwired - Jul 6, 2016) - Plandaí Biotechnology, Inc. (OTCQB: PLPL) ("Plandaí" or "the Company"), producer of the highly bioavailable Phytofare® catechin complex, today discussed the recent filing of the Company's financial statements for the year ended June 30, 2015, filed last week on Form 10-K, and announced that the quarterly reports for the first, second and third quarters of the current year being prepared for review. The Company anticipates that all delinquent filings will be made in the coming weeks with a goal of being fully reporting and relisted on the OTCQB by the end of August 2016.
Roger Baylis-Duffield, Chairman and Chief Executive Officer of Plandaí, commented, "The past several months have been exhausting as we were forced to change auditors and then re-audit 2014 on top of 2015. We wanted to ensure that our filings were beyond reproach, so the process took longer than any of us anticipated. With that said, our commitment is to remain current on our filings going forward so that our shareholders have timely and accurate financial information."
In addressing the June 30, 2016 operating results, Mr. Baylis-Duffield stated, "In January 2016 we finally began selling our inaugural product, Phytofare® Catechin Complex, a green-tea derived extract high in bioavailability that contains all eight catechins. Thus far, the market has been accepting. Phytofare®, as a premium product, is not comparable to generic green tea and thus customers cannot simply swap out to our ingredient. Besides subjecting Phytofare® to a battery of tests, customers need to change over all their packaging, labeling and, in some cases, rework their product formulations. All of this translates into a fairly long buy cycle. With this said, revenues have been steadily growing and we booked around $175,000 in Phytofare® sales over the first six months of 2016.
"Going forward," Mr. Baylis-Duffield added, "we expect to maintain current sales level of between 300-400kg per month through September 2016. At that point, weather permitting, we can recommence production and expect to grow sales from October 2016 forward until we reach the two tons per month level. We are finalizing the manufacturing and processing specifications for our solvent-free Phytofare® Citrus Complex and hope to have an announcement soon on this product's availability to the market."
"With respect to our research for the animal husbandry industry," Mr. Baylis-Duffied stated, "Plandaí is working on a commercial solution to improve poultry health, lower mortality and control diseases, all of which represent higher profits to the producer and healthier products to the consumer. We are commencing a three-phase clinical investigation in South Africa to confirm that pH2 catechins™ inhibit pathogens naturally found in the intestinal tract of poultry and which are the primary cause of the most common and financially devastating bacterial diseases in modern broiler flocks. The first of these studies is set to commence next week and we would like to be complete with all studies by the end of the year."
Mr. Baylis-Duffield concluded, "While ongoing reporting delays hampered operations to an extent in 2016, we were able to successfully launch Phytofare® into the market. We have had encouraging levels of sales in Europe and Africa, and developed a solid sales structure in North America that should soon start generating significant results. We are grateful to be over the hurdled and excited to start the new fiscal year."
Lt. Chart ist ein Zwischenstep bei 0,10 Dollar - danach, falls es zu einem Durchbruch
nach oben kommt - sind durchaus auch 0,50 Dollar denkbar.
Aber Gemach, wir lassen jetzt mal Tag für Tag vorübergehen, dann sehen wir was in 9 Wochen
am 31.12. auf der Kurstafel steht :-)
noch nicht richtig mitbekommen haben......
Mal sehen ob wir vielleicht heute schon Richtung 7-8-9 US-Cent laufen können. ???